Study #2024-0220
GATE1: A multicenter phase II study of pirtobrutinib, rituximab and venetoclax combination therapy for patients with previously untreated mantle cell lymphoma
MD Anderson Study Status
Enrolling
Treatment Agent
Pirtobrutinib, Rituximab, Venetoclax
Description
Primary Objectives: To estimate the percent of participants who achieve a best response of complete response by the end of the PRV combination therapy in the induction therapy phase in patients with previously untreated MCL.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Mantle Cell Lymphoma
Study phase:
Phase II
Physician name:
Michael Wang
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-833-759-1892
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.